The Medical Advisor

By Dr. Frank Yap, MD  · One Day Media Network · Medically reviewed · Updated October 19, 2026 · Originally published April 2025 Quick Answer The hallmarks of cancer are the core capabilities tumors acquire to grow, survive, spread and evade immunity. Hanahan’s 2026 Cell update organizes them into nine hallmarks (phenotypic plasticity is now a full hallmark), five enabling characteristics , seven classes of hallmark-facilitating normal cells and two systemic influences (aging and obesity). Every hallmark has approved oncology drugs (CEBM Level 1). Repurposed drugs and supplements mostly sit at Level 3–5 (observational, case reports, preclinical). ASCO’s May 2026 notice advises against ivermectin and fenbendazole for cancer outside clinical trials. This page maps each hallmark to what is approved, what is investigational, and what is only hypothesis. Table of Contents What changed in the 2026 hallmarks framework How to read the evidence tiers Master table: ha...

Home › GLP-1 Hub By Dr. Frank Yap, MD | One Day Media Network | Published October 13, 2026 | Last updated: October 13, 2026 | Purpose: evidence and safety education, not individual medical advice Quick Answer As of October 2026, the FDA has approved two GLP-1 weight-loss pills, oral Wegovy (semaglutide 25 mg, December 2025) and Foundayo (orforglipron, April 1, 2026), alongside weekly injections such as Wegovy, Zepbound, Ozempic and Mounjaro. Retatrutide and CagriSema are not approved in the US. Compounded and gray-market GLP-1 products are not FDA-approved. Use a licensed prescriber and a regulated pharmacy. On this page Which GLP-1 medicines are approved in October 2026? Are GLP-1 pills as effective as injections? Retatrutide and CagriSema: what is known so far? Safety and side effects: what should patients know? Compounded, gray-market and research peptides: what are the risks? How strong is the evidence? (CEBM grades) Where to start: the complete GLP-1 evidence library Using...